Disease · MONDO_0001628

tinea unguium

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. tinea unguium. Diseases, record MONDO_0001628. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001628

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: tinea unguium; Open Targets
Open Targets ID: MONDO_0001628; Open Targets
Other names: dermatophytic onychia, dermatophytosis of nail, nail dermatophytosis, onychomycosis; Open Targets
Disease Ontology: DOID:13074; Disease Ontology
MeSH: D014009; MeSH
NCI Thesaurus: C112214; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 30 drugs, from PMDA and TTD; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAVABOROLE	CHEMBL443052	Small molecule	Approval	TTD	11	10	10	Drugs and targets
EFINACONAZOLE	CHEMBL2103877	Small molecule	Approval	PMDA	10	9	9	Drugs and targets
AMOROLFINE	CHEMBL489411	Small molecule	Approval	TTD	9	8	8	Drugs and targets
LULICONAZOLE	CHEMBL2105689	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
TIOCONAZOLE	CHEMBL1200438	Small molecule	Approval	TTD	2	1	1	Drugs and targets
TRIACETIN	CHEMBL1489254	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TERBINAFINE	CHEMBL822	Small molecule	Phase 3	ClinicalTrials.gov and TTD	15	13	12	Drugs and targets
ITRACONAZOLE	CHEMBL64391	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
TERBINAFINE HYDROCHLORIDE	CHEMBL1200832	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CICLOPIROX	CHEMBL1413	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS1	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	1	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets
RARA	Retinoic acid receptor	1	Retinoic acid receptor agonist	Phase 1	https://conductscience.org/library/genes/5914	Drugs and targets
RARB	Retinoic acid receptor	1	Retinoic acid receptor agonist	Phase 1	https://conductscience.org/library/genes/5915	Drugs and targets
RARG	Retinoic acid receptor	1	Retinoic acid receptor agonist	Phase 1	https://conductscience.org/library/genes/5916	Drugs and targets

Trials59

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00356915	Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.	Phase 3	1,381	2012-01-04	Onychomycosis	ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01302119	Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail	Phase 3	604	2014-08-15	Onychomycosis of Toenails	TAVABOROLE	Its record names the disease	ClinicalTrials.gov
NCT01270971	Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail	Phase 3	594	2014-08-15	Onychomycosis of Toenails	TAVABOROLE	Its record names the disease	ClinicalTrials.gov
NCT00730405	Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis	Phase 2	582	2018-02-07	Onychomycosis	ALBACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00443898	Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail	Phase 3	518	2011-04-20	Onychomycosis	TERBINAFINE	Its record names the disease	ClinicalTrials.gov
NCT02267356	A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail	Phase 2	259	2020-11-04	Onychomycosis	OTESECONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00491764	A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)	Phase 2	218	2010-01-28	Onychomycosis	POSACONAZOLE, TERBINAFINE	Its record names the disease	ClinicalTrials.gov
NCT00791219	Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis	Phase 2	175	2020-08-25	Onychomycosis	ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT02812771	Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis	Phase 4	62	2021-11-01	Onychomycosis	EFINACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT03405818	An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents	Phase 4	55	2018-04-17	Onychomycosis, Tinea Unguium	TAVABOROLE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 59

See all 59 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AN2690 Topical Solution, 5% vs Solution Vehicle: serious adverse events	7 of 395	2 of 202	597	NCT01302119	Trial comparisons
AN2690 Topical Solution, 5% vs Solution Vehicle: serious adverse events	12 of 396	8 of 193	589	NCT01270971	Trial comparisons
Efinaconazole 10% and Nail Polish vs Efinaconazole 10% Without Nail Polish: deaths from any cause	0 of 7	0 of 6	13	NCT03110029	Trial comparisons
Efinaconazole 10% and Nail Polish vs Efinaconazole 10% Without Nail Polish: serious adverse events	0 of 7	0 of 6	13	NCT03110029	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24352873	RESULT	1	PubMed
24079585	RESULT	1	PubMed
22565425	RESULT	1	PubMed
19968146	RESULT	1	PubMed
14964746	RESULT	1	PubMed
39158295	DERIVED	1	PubMed
32421854	DERIVED	1	PubMed
30811142	DERIVED	1	PubMed
30051298	DERIVED	1	PubMed
25007364	DERIVED	2	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001628

GET https://conductscience.org/api/diseases/v1/MONDO_0001628/drugs?page=2

API reference For AI assistants